Why the study?
Inhibition of platelet glycoprotein VI reduces thrombosis without impairing hemostasis, making it a promising antithrombotic approach.
Comparison
Glenzocimab and Revacept
Design
Review
Key result
Inhibition of platelet glycoprotein VI (GPVI) with drugs like glenzocimab and Revacept reduces thrombosis without impairing hemostasis, representing a promising antithrombotic approach.
Authors
Loading...
May inform safer antithrombotic development in high-risk patients; leaves open phase 3 confirmation of net benefit.
Targeting platelet glycoprotein VI (GPVI) with investigational drugs like glenzocimab and Revacept represents a promising antithrombotic strategy that may reduce thrombosis without significantly increasing bleeding risk.
Li et al. (2025) conducted a review in Thrombosis. GPVI-targeting drugs (glenzocimab and Revacept) was evaluated. Inhibition of platelet glycoprotein VI (GPVI) with drugs like glenzocimab and Revacept reduces thrombosis without impairing hemostasis, representing a promising antithrombotic approach.